The Biggest Resistance-Training Study in 17 Years, Explained @BarbellMedicine

Uploaded July 2026 | Updated September 2026, 3 weeks ago

The ACSM published its first resistance-training position stand since 2009, an overview of 137 systematic reviews. We translate it: training to failure is optional, the useful load range is wider than people think, and what matters most is how much you do and how hard.

Chapters:
0:00 The first ACSM update since 2009
1:14 What changed: failure optional, load flexible
5:22 Putting it into practice (the clinician view)
10:00 What would make it even better

Resources

Barbell Medicine coaching and templates: barbellmedicine.com

barbellmedicine.com/shop/subscriptions/plus-podcast-subscription

barbellmedicine.com/shop/subscriptions/barbell-medicine-premium

Signal book pre-order: barbellmedicine.com/shop/learning/signal

References:
ACSM Position Stand (2026), Phillips SM et al., Med Sci Sports Exerc: pubmed.ncbi.nlm.nih.gov/41843416

The Biggest Resistance-Training Study in 17 Years, Explained

What Actually Determines Your Weight? Genetics, the Set Point Myth, and the Defended Range

Episode #378: Bulletproof or Broken- Why Perfect Form Is a Lie

Endometriosis and the Lifter: Training, Nutrition, and Pain

Do You Actually Have to Train to Failure?

$Fen-Phen, Vioxx, and What a Missing Drug Trial Actually Costs Before you decide a missing trial does not matter, look at what happened the last three times. Fen-phen, Vioxx, and a compounding-pharmacy meningitis outbreak that killed 64 people all followed the same structure that is in front of the FDA now. This segment lays out each one and what it should teach you about approving drugs on thin evidence. Timestamps: 00:00 What a missing trial costs 00:10 Fen-phen 02:28 Redux: a second panel says yes by one vote 03:28 Vioxx 05:20 The FDA got the science right and still could not act 05:38 The New England Compounding Center 07:08 The law that came out of it 07:50 No safety data is not probably safe 08:03 What the animal and adverse-event data show Resources: Barbell Medicine coaching and templates: https://www.barbellmedicine.com Plus podcast subscription: https://www.barbellmedicine.com/shop/subscriptions/plus-podcast-subscription/ Barbell Medicine Premium: https://www.barbellmedicine.com/shop/subscriptions/barbell-medicine-premium/ Signal (book pre-order): https://www.barbellmedicine.com/shop/learning/signal/ References: 1. FDA. PCAC briefing document. Jul 23-24, 2026. 2. FDA. BPC-157 bulk substance review. PCAC 2026. fda.gov/media/193343 3. FDA. TB-500 bulk substance review. PCAC 2026. Media 193349. 4. FDA. KPV, MOTS-c, Semax, Epitalon, Emideltide reviews. 2026. 5. FDA. Questions for the PCAC. Jul 2026. 6. FDA. PCAC roster 2026. Media 193772. 7. FDA. PCAC roster 2022. Media 159040. 8. openFDA. FAERS reports, BPC-157. open.fda.gov 9. 21 CFR 216.23 (2026). 10. FD&C Act 503A; 21 USC 353a. 11. Abigail Alliance v von Eschenbach, 495 F3d 695 (DC Cir 2007). 12. US v Rutherford, 442 US 544 (1979). 13. Right to Try Act of 2017, Pub L 115-176. 14. FDA. Peptide drug products. Draft guidance, 2020. 15. Ruenzi. PL 14736 (BPC 157) in ulcerative colitis. Gastroenterology 2005; abstract only. 16. Staresinic. BPC 157, transected rat quadriceps. J Orthop Res 2006;24:1109. 17. Gwyer. BPC 157 and soft tissue healing. Cell Tissue Res 2019;377:153. 18. Sikiric. BPC 157, hemorrhage/thrombosis. Pharmaceuticals 2026;19:463. 19. Stavchansky. Glyprolines and gene expression, Semax. Genes 2022;13:2380. 20. Mendias. Approved and unapproved peptides. Sports Med 2026. 21. Moseley. Arthroscopic surgery for knee OA. NEJM 2002;347:81. 22. Cobb. Internal mammary ligation, double-blind. NEJM 1959;260:1115. 23. Dimond. IMA ligation vs sham for angina. Am J Cardiol 1960;5:483. 24. Alfredson. Eccentric calf training, Achilles tendinosis. AJSM 1998;26:360. 25. Kongsgaard. Steroid vs exercise, patellar tendinopathy. Scand J Med Sci Sports 2009;19:790. 26. Langberg. Peritendinous metabolism during exercise. J Physiol 1999;515:919. 27. Coombes. Steroid vs physiotherapy, tennis elbow. JAMA 2013;309:461. 28. Kearney. PRP vs sham, Achilles tendinopathy. JAMA 2021;326:137. 29. Pavlova. Exercise dose in tendinopathy, meta-analysis. BJSM 2023;57:1327. 30. Weintraub. Fen-phen vs placebo. Clin Pharmacol Ther 1992;51:586. 31. Connolly. Valvular heart disease with fen-phen. NEJM 1997;337:581. 32. CDC. Valvulopathy with fenfluramine. MMWR 1997;46:1061. 33. Bombardier. VIGOR: rofecoxib vs naproxen. NEJM 2000;343:1520. 34. Graham. MI and sudden death, COX-2 inhibitors. Lancet 2005;365:475. 35. Smith. Fungal infections, contaminated methylprednisolone. NEJM 2013;369:1598. 36. Adunsky. MK-0677 after hip fracture. Arch Gerontol Geriatr 2011;53:183. Halted early, CHF signal. 37. Nass. Oral ghrelin mimetic in older adults. Ann Intern Med 2008;149:601. 38. Van Wagoner. Composition of SARMs sold online. JAMA 2017;318:2004. 39. ECRI/ISMP. Unapproved peptide products. Apr 2026. 40. CSPI. Are injectable peptides safe? cspinet.org 41. WADA. 2026 Prohibited List. wada-ama.org 42. USADA. BPC-157: a prohibited peptide. usada.org 43. Time. FDA panel backs compounding peptides. Jul 2026. 44. RAPS. Committee backs controversial peptides. 2026. 45. STAT. Panel okays peptides for compounding. Jul 2026. 46. NBC News. Panel eases peptide limits over FDA objections. 2026. 47. AP. Financial ties among FDA peptide panel members. 2026. 48. Leerink. PCAC vote and telehealth compounding market. 2026. 49. Examine.com. BPC-157 research breakdown. examine.com/supplements/bpc-157/ 50. Jarry. BPC: no proof required. McGill OSS. mcgill.ca/oss$

Is It Really Just Calories In, Calories Out? Metabolism, Insulin, Hormones and Why Counting Fails

GLP-1 Muscle Loss and Creatine, Bulking Myths & How Fast You Lose Gains

Menopause, Part 2: The 2,000-Year-Old Lie About Women and Exercise

Barbell Medicine |

The Biggest Resistance-Training Study in 17 Years, Explained